Serum concentration of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) correlates with markers of the disease activity in early rheumatoid arthritis;Stȩżenie tkankowego inhibitora metaloproteinaz-1 (TIMP-1) w surowicy koreluje z wskaźnikami aktywności choroby we wczesnym okresie reumatoidalnego zapalenia stawów

Polskie Archiwum Medycyny Wewnetrznej

Volumn 115, Issue 1, 2006, Pages 13-17

  Fiedorczyk, Małgorzata ^a   Klimiuk, Piotr Adrian ^a,b   Sierakowski, Stanisław ^a   Gińdzieńska Sieśkiewicz, Ewa ^a   Chwiećko, Justyna ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Klinika Reumatologii i Chorob Wewnetrznych   (Poland)

Author keywords

Early rheumatoid arthritis; Tissue inhibitors of metalloproteinases

Indexed keywords

ANTIRHEUMATIC AGENT; CORTICOSTEROID DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; BIOLOGICAL MARKER; C REACTIVE PROTEIN; METHOTREXATE; RHEUMATOID FACTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; DISEASE MARKER; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; ADULT; AGED; BLOOD; DRUG EFFECT; EARLY DIAGNOSIS; MIDDLE AGED;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; RHEUMATOID FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 33745919228     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Filipowicz-Sosnowska A.: Reumatoidalne zapalenie stawów. Medipress Medical Update 2002, suppl. 3, 3.
2. Firestein G.S.: Etiology and pathogenesis of rheumatoid arthritis. [w:] Textbook of rheumatology. Red.: Kelley W.N., Harris E.D., Ruddy S., Sledge C.B., Philadelphia, WB Saunders Company, 1997, 851.
3. Huizinga T.W.J., Machold K.P., Breedveld F.C., Lipsky P.E., Smolen J.S.: Criteria for early rheumatoid arthritis. From Bayes' law revisited to new thoughts on pathogenesis. Arthritis Rheum., 2002, 46, 1155.
4. Szechiński J., Wiland P.: Wczesne reumatoidalne zapalenie stawów. Górnicki Wydawnictwo Medyczne, Wrocław 2004, 1-135.
5. Filipowicz-Sosnowska A., Przygodzka M., Za̧bek J.: Wczesne reumatoidalne zapalenie stawów w aspekcie diagnostyki różnicowej. Reumatologia, 2001, 39, 3.
6. Sokka T., Willoughby J., Yazici Y., Pincus T.: Databases of patients with early rheumatoid arthritis in the USA. Clin. Exp. Rheumatol., 2003, 21 (suppl. 31), S146-S153.
7. Nagase H., Okada Y.: Proteinases and matrix degradation. [w:] Textbook of rheumatology. Red.: Kelley W.N., Harris E.D., Ruddy S., Sledge C.B., Philadelphia, WB Saunders Company, 1997, 323.
8. Ahrens D., Koch A.E., Pope R.M. i wsp.: Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum., 1996, 39, 1576.
9. Fosang A.J., Neame P.J., Last K. i wsp.: The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J. Biol. Chem., 1992, 267, 19470.
10. Emery P., Symmons D.P.M.: What is early rheumatoid arthritis?: definition and diagnosis. Baillieres Clin. Rheumatol., 1997, 11, 13.
11. Fuchs H.A., Kaye J.J., Callahan L.F. i wsp.: Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J. Rheumatol., 1989, 16, 585.
12. Scott D.L., Smith C., Kingsley G.: Joint damage and disability in rheumatoid arthritis: an updated systematic review. Clin. Exp. Rheumatol. 2003, 21, (suppl. 31), S20-S27.
13. Emery P., Breedveld F.C., Dougados M. i wsp.: Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann. Rheum. Dis., 2002, 61, 290.
14. Quinn M.A., Emery P.: Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin. Exp. Rheumatol., 2003, 21 (suppl. 31), S154-S157.
15. Matrisian L.M.: Matrix metalloproteinase gene expression. Ann. N. Y. Acad. Sci., 1994, 732, 42.
16. Borden P., Heller R.A.: Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit. Rev. Eukaryot. Gene. Expr., 1997, 7, 159.
17. Cawson T.: Matrix metalloproteinases and TIMPs: properties and implications for the rheumatoid arthritis. Mol. Med. Today, 1998, 4, 130.
18. Martel-Pelletier J.: Metalloproteinases and inhibitors in arthritic disease. Best Pract. Res. Clin. Rheumatol. 2001, 15, 805.
19. Brew K., Dinakarpandian D., Nagase H.: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta., 2000, 1477, 267.
20. Murphy G., Willenbrock F.: Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol., 1995, 248, 496.
21. Szabo K.A., Ablin R.J., Singh G.: Matrix metalloproteinases and the immune response. Clin. Applied Immunol. Rev., 2004, 4, 295.
22. Firestein G.S., Paine M.M., Littman B.H.: Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium. Quantitative analysis and effect of intraarticular corticosteroids. Arthritis Rheum., 1991, 34, 1094.
23. Wong P., Cuello C., Bertouch J.V. i wsp.: The effects of pulse methylprednisolone on matrix metalloproteinase and tissue inhibitor of metalloproteinase-1 expression in rheumatoid arthritis. Rheumatology (Oxford) 2000, 39, 1067.
24. Okada Y., Gonoji Y., Naka K. i wsp.: Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J. Biol. Chem., 1992, 267, 21712.
25. Keyszer G., Lambiri I., Nagel R. i wsp.: Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J. Rheumatol., 1999, 26, 251.
26. Yoshihara Y., Obata K., Fujimoto N. i wsp.: Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum., 1995, 38, 969.
27. Klimiuk P.A., Sierakowski S., Chwiećko J.: Korelacje pomiȩdzy stȩżeniem czynnika martwicy nowotworów α a stȩżeniem metaloproteinaz w surowicy chorych na reumatoidalne zapalenie stawów. Pol. Merk. Lek., 2003, 83, 410.
28. Klimiuk P.A., Sierakowski S., Latosiewicz R. i wsp.: Serum metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid arthritis. Rheumatology (Oxford) 2002, 41, 78.
29. Cunnane G., Fitz Gerald O., Beeton C. i wsp.: Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum., 2001, 44, 2263.
30. Klimiuk P.A., Sierakowski S., Domysławska I., Chwiećko J.: Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. J. Rheumatol., 2004, 31, 238.